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Abstract
Background: Aortic valve calcification shares risk factors with coronary artery disease. Coronary calcium has been
used has a gatekeeper to performing coronary tomography angiography. The aim of this study was to evaluate
aortic valve calcification as a predictor of obstructive coronary artery disease by computed tomography, and its
possible usefulness, alongside with coronary calcium, to improve the decision of whether or not to proceed with
computed tomography angiography.
Methods: Transversal case–control study including 154 consecutive patients (62 ± 12 years, 57.6 % female, without
known coronary or valve disease) undergoing calcium scoring and angiography through computed tomography
(Phillips Brilliance, 16-slice). Predictors of aortic valve calcification and obstructive coronary artery disease were
identified. Usefulness of aortic valve calcification when added to calcium score for prediction of obstructive
coronary artery disease was assessed by binary logistic regression and net reclassification index.
Results: Aortic valve calcification was associated with higher coronary calcium, extent and prevalence of
obstructive coronary disease, which was identified in 22.1 % of patients and was discriminated by aortic valve
calcium with an area under curve 0.749 (p < 0.001, Youden index: 61). A higher discriminative power was achieved
with a model based on coronary and aortic valve calcification (AUC 0.900, p < 0.001). Compared with calcium score >400
as a gatekeeper to angiography, the association of aortic calcium >61 allowed a net reclassification index of +7.7 % of
patients.
Conclusions: Aortic valve calcification is associated with the prevalence and extent of obstructive coronary artery disease
by computed tomography angiography and is an easy, fast and useful method to improve the selection of patients for
angiography.
Keywords: Aortic valve calcification, Cardiac computed tomography, Coronary artery calcification, Coronary artery disease,
Coronary CT angiography
Background
Coronary artery calcium (CAC) can be assessed by using
non-contrast cardiac computed tomography, with low ra-
diation exposure, and is usually assessed through the
“Agatston score”. This is a marker of coronary atheroscler-
osis and reflects the total atherosclerotic burden, including
calcified and non-calcified plaques [1].
CAC has been extensively validated as a marker of car-
diovascular risk, with values greater than or equal to 400
allowing reclassification of low/intermediate-risk asymp-
tomatic patients into high risk [2].
CAC also has also been associated with coronary lu-
minal stenosis, with high specificity (>72 %%) for values
over 310 – 400 [3, 4]. Due to this surrogate value of CAC
to predict coronary stenosis, its use has been suggested as
a gatekeeper to the use of cardiac computed tomography
(CT) angiography (CTA) for diagnosing significant coron-
ary artery disease (CAD) in patients with chest pain [5].
The appropriate use criteria for CT published in 2010
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considered inappropriate to perform a CTA for CAC score
values higher than 400 [6]. Guidelines from the National
Institute of Health and Clinical Excellence also recommend
opting for CTA in CAC scores of 1–400 and choosing
invasive angiography in CAC scores above 400 [7].
Aortic valve calcification (AoVC) shares some risk factors
with CAD [8] and is believed to be associated with cardio-
vascular risk [9, 10], coronary plaque burden [11, 12] and
severity of angiographic coronary artery disease [13]. How-
ever, its role as a predictor of obstructive CAD identified by
CTA and its possible usefulness, on top of the calcium
score, is unknown. The reproducibility of AoVC measure-
ment by CT has been previously reported [14], and can be
reliably measured using the “Agatston score” in the same
acquisition of CAC, without contrast or additional radi-
ation exposure [8–14].
This study aims to evaluate AoVC, identified by CTA,
as a predictor of obstructive CAD and the usefulness of
combining AoVC and CAC score to decide whether or
not to proceed with CTA.
Methods
Study design
Transversal case–control single centre study including
patients referred for assessment of possible CAD using
CT. CAC and CTA were performed. Clinical and labora-
torial data were collected. This study was approved by
our Institution’s Cardiology Department Supervisor and
Ethics Committee in December 2008. All patients pro-
vided informed consent before undergoing CT.
Patients and eligibility criteria
A total of 154 consecutive patients, without known his-
tory of severe aortic stenosis or coronary artery disease,
were referred for CT for evaluation of coronary artery
disease, in a non-acute setting, between January 8, 2009,
and September 30, 2010. Patients over 18 years old were
included in the study. Exclusion criteria were contraindi-
cation to iodine-based contrast agents, glomerular filtra-
tion rate <30 mL/min, pregnancy, inability to sustain a
15-s breath-hold, cardiac arrhythmias or uninterpretable
CTA.
Initial data collection
An extensive review of clinical records from our out-
patient clinic, hospital ward and emergency department
admission(s), was performed by 2 co-investigators, and
the following data were collected: demographic features,
cardiovascular risk factors, cardiovascular risk scores
(SCORE [15] and Framingham [16]), previous medical
history (including history of CAD and severe aortic sten-
osis), physical examination (including weight, height,
body mass index, blood pressure and heart rate) and
analytical study: total cholesterol, triglyceride, high
density lipoprotein cholesterol, low density lipoprotein
cholesterol, serum creatinine and C-reactive protein.
GFR was calculated by MDRD (Modification of Diet in
Renal Disease) formula.
Hypertension, dyslipidemia and diabetes were defined
by self-reporting during history-taking and/or history or
use of specific therapy. Family history of CAD was de-
fined as fatal or non-fatal myocardial infarction or cor-
onary revascularisation in first-degree male relatives
<55 years or first degree female relatives <65 years. His-
tory of cigarette smoking was considered present if a
subject was a current or former smoker.
CT data acquisition
All scans were performed using a 16-slice CT scanner
(Brilliance 16; Philips Medical Systems, Eindhoven, the
Netherlands). A prospective scan without contrast en-
hancement was performed to measure CAC and AoVC
(sequential scan with 8 × 3 mm collimation, tube current
55mAs at 120 kV, 3 mm width), followed by 16-slice
contrast-enhanced spiral scan of the heart performed
with ECG gating and retrospective post processing. CTA
parameters: 16 × 0.75 mm collimation, 400 ms gantry ro-
tation, pitch of 0.298, tube voltage at 120 kV, maximum
current of 600—800 mAs depending on patient size,
half-scan reconstruction mode and imaging craniocaudal
direction. All patients received 5 mg of sublingual iso-
sorbide dinitrate 5 min before CTA acquisition. Patients
with a heart rate >65 bpm received 50-200 mg of oral
metoprolol. A bolus (120-130 mL) of iodinated contrast
agent (370 mOsm) was intravenously injected (4–5.5 ml/s).
A region of interest was placed in the descending thoracic
aorta and image acquisition was automatically initiated
using bolus tracking (selected threshold: 110 Hounsfield
units [HU]). Images were reconstructed in five phases of
the cardiac cycle (0, 37.5, 62.5, 75 and 87.5 % of the R-R
interval) to minimize motion artifacts. The estimated ef-
fective radiation dose used was: per CAC and AoVC - me-
dian 0,8 mSv (maximum: 0,32 mSv; minimum: 1.28 mSv);
per CTA – median 10,44 mSv, maximum 17,44 mSv, mini-
mum 9,24 mSv (CTA per se: median 10 mSv, maximum
17 mSv, minimum 8,8 mSv; Locator: median 0,44 mSv,
maximum 1,28 mSv, minimum 0,32 mSv); per complete
scan: median 11 mSv (maximum 18 mSv, minimum
10 mSv).
CT Image interpretation
CTA image evaluation was performed on a separate 3D
workstation (Brilliance workstation, Philips Medical Sys-
tems, Eindhoven, the Netherlands) by two experienced
reviewers. CTA were analysed by assessment of axial
slices, multiplanar reformations (along the vessel axis
and cross-sectional images), and the three thin-slab
maximum intensity projections. The coronary artery tree
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was divided into proximal, medial and distal, according
to classic angiographic definition. Plaques were classified
as obstructive or non-obstructive using a 50 % threshold
of luminal narrowing. The presence of obstructive CAD
was defined by >50 % lumen narrowing, and was classi-
fied according to the number of vessels with obstructive
CAD: single-vessel disease (one vessel) or multivessel
disease (two or three vessels). Plaques were defined as
structures >1 mm2 within and/or adjacent to the vessel
lumen, distinct from lumen and surrounding tissue. Pla-
ques were classified as: calcified – if they had more than
50 % calcified tissue (density >130HU in native scans),
mixed – if composed with <50 % calcium, and non-
calcified lesions - without any calcium. After independ-
ent assessment, the final diagnosis was obtained by a
consensus interpretation of the two reviewers.
CAC and AoVC were measured using a workstation
(Aquarius iNtuition, version 4.4, Tera Recon, Inc, San
Mateo, CA, USA). CAC was measured for each patient
using the automatic calcium detection algorithm of the
workstation, according to Agatston method, with a cal-
cium threshold of 130 HU. AoVC was measured and
quantified with the same lesion definition, the same soft-
ware and the same acquisition of CAC. The presence of
AoVC was defined as any calcified lesion detected within
the aortic valve leaflet area or extending to the aortic
root. Calcium within the aortic sinuses or thoracic aorta
was excluded from analysis and not measured as AoVC.
Study endpoints
The primary endpoint of this study was detection of ob-
structive CAD by CTA.
The secondary endpoint was the identification of pa-
tients with CAC <400 and AoVC >61 or AoVC >454
with obstructive CAD.
Statistical analysis
Statistical analysis was performed using SPSS, v. 17.0.
Baseline characteristics were described with counts and
proportions for categorical data; continuous variables
with normal distribution were described by mean ±
standard deviation, while continuous variables with non-
normal distribution were described with median, mini-
mum and maximum value. The Kolmogorov-Smirnov
test was used to test the normal distribution of continu-
ous variables. The Chi-square test, Student’s t-test and
non-parametric equivalent tests were used when appro-
priate. Regression estimation techniques were applied to
replace missing values whenever the number of missing
values was negligible, otherwise cases with missing
values would be omitted. P values <0.05 (two-sided)
were considered statistically significant.
A comparative analysis was performed to evaluate po-
tential predictors of AoVC. Three cutoffs were used for
this purpose: AoVC ≥ 1 (presence of any aortic valve cal-
cification), AoVC > 61 (threshold defined according to
the Youden index on ROC curve analysis - optimal sen-
sitivity and specificity: 66.7 % sensitivity and 76.7 % spe-
cificity) and AoVC > 454 (cutoff of AoVC with
equivalent specificity (95.8 %) to that of CAC > 400 for
obstructive CAD in our sample). We also performed a
comparative analysis to evaluate a potential association
with obstructive CAD. Potential predictors presented as
continuous variables were converted into binary vari-
ables using as cutoff point the Youden index. Binary lo-
gistic regression analysis was performed to identify,
among potential associations, the independent predic-
tors of AoVC and obstructive CAD. A predictor model
of obstructive CAD was created using CAC and AoVC
(PM CAC+ AoVC) using continuous variables in binary
logistic regression with the method Enter; regression co-
efficients obtained were then applied to calculate pre-
dicted risks according to predictor model. The
discriminatory power for predicting obstructive CAD
using AoVC, CAC, Framingham, SCORE and the pre-
dictor model was then evaluated through receiver oper-
ating characteristic (ROC) curves. Comparisons of areas
under ROC curves (AUC) were performed using Med-
Calc for Windows version 9.2.0.1.
Finally, the net reclassification improvement (NRI)
was calculated according to the method described by
Pencina et al. [17] to quantify the reclassification with
CAC > 400 or AOVC > 61/ or >454, comparatively with
CAC > 400, as a gatekeeper for CTA. A positive and sig-
nificant NRI translates a net overall successful reclassifi-
cation of subjects into more appropriate risk categories
(e.g. a patient who reaches the primary endpoint that is
reclassified into higher risk groups with CAC and AoVC
or a subject who does not reach the primary endpoint
that is reclassified into a lower risk category with CAC
and AoVC). The amount of overall reclassification is
translated by the extent of the NRI (a per cent value). A
positive NRI value represents an adequate reclassifica-
tion into the correct risk category, whereas a negative




One hundred and fifty-four patients were referred for
CT. Demographic, clinical and laboratorial characteris-
tics of study population are summarized in Table 1.
CT results
The median CAC was 20.6 (0; 5515.6) and median
AoVC was 9.1 (0; 3667.5). A CAC score of zero was ob-
served in 59 patients (38.3 %) and 54 patients (35.1 %)
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had an AoVC of zero. Obstructive CAD was identified
by CTA in 34 patients (22.1 %).
Predictors of AoVC
On univariate analysis, for the different cutoffs of AoVC,
patients with higher levels of AoVC were older, had
higher pulse pressure, higher cardiovascular risk by
SCORE, higher prevalence of calcified plaques, of ob-
structive CAD and number of vessels with obstructive
CAD (Table 2). Higher values of CAC were also associ-
ated to higher values of AoVC for all assessed cutoffs
(Table 2). A higher prevalence of atherosclerosis was ob-
served in patients with AoVC values ≥1 and >61, but
not in those with AoVC >454 (Table 2). On multivariate
analysis, age was an independent predictor of AoVC for
all the cutoffs, while pulse pressure was independent
predictor of any calcification and of AoVC >454. Ob-
structive CAD predicted AoVC > 61 (Table 3).
AoVC as predictor of obstructive CAD
On univariate analysis, obstructive CAD was associated
with male gender, dyslipidemia, age > 64 years, SCORE ≥
3, CAC >400, AoVC ≥1, AoVC >61 and AoVC >454
(Table 4). Using a general linear model, AoVC remained
associated with obstructive CAD after adjustment for
Table 1 Study population baseline characteristics
Patient baseline characteristics
Age (years: mean ± sd) 62 ± 12
Female, % (n) 57.6 % (88)
Caucasian, % (n) 100 % (154)
Cigarette smoking, % (n) 14.9 % (23)
Hypertension, % (n) 83.8 % (129)
Dyslipidemia, % (n) 63.6 % (98)
Family history of CAD, % (n) 3.9 % (6)
Body mass index (Kg/m2, mean ± sd) 28.7 ± 4.2
Framingham (median [minimum; maximum]) 10 [1; 54]
SCORE (median [minimum; maximum]) 2 [0; 16]
Glomerular filtration rate (mL/min/1.73 m2, mean ± sd) 86.7 ± 22.7
Total cholesterol (mmol/L, mean ± sd) 5.2 ± 1.2
LDL cholesterol (mmol/L, mean ± sd) 3.0 ± 0.9
HDL cholesterol (mmol/L, mean ± sd) 1.3 ± 0.5
Triglycerides (mmol/L, mean ± sd) 1.0 ± 0.9
C-reactive protein (mg/dL: median [minimum; maximum]) 0.6 [0.1; 2.1]
Table 2 Predictors of Aortic Valve calcification on univariate analysis
Predictors of AoVC: univariate analysis AoVC ≥1 AoVC >61 AoVC >454
AoVC ≥1 AoVC =0 p AoVC >61 AoVC ≤61 p AoVC >450 AoVC ≤454 p
Male gender 44 % 40.7 % 0.697 36 % 46.2 % 0.233 38.5 % 43.3 % 0.738
Dyslipidemia 70.4 % 84.9 % 0.054 69.4 % 62.7 % 0.423 75 % 64 % 0.445
Diabetes 26.5 % 18.9 % 0.292 22.4 % 24.5 % 0.781 16.7 % 24.5 % 0.543
Smoking 12.2 % 20.8 % 0.165 8.2 % 18.6 % 0.094 8.3 % 15.8 % 0.488
Family history 3.2 % 5.9 % 0.437 0 % 6.3 % 0.074 0 % 4.5 % 0.452
SBP (mmHg) 149 ± 23 137 ± 23 0.003 148 ± 24 143 ± 23 0.248 155 ± 23 144 ± 24 0.105
DBP (mmHg) 76 ± 13 80 ± 12 0.061 75 ± 12 78 ± 13 0.111 75 ± 14 77 ± 13 0.499
PP (mmHg) 73 ± 22 58 ± 19 <0.001 73 ± 21 65 ± 23 0.032 80 ± 26 67 ± 22 0.036
Age (years) 66 ± 10 54 ± 12 <0.001 71 ± 8 58 ± 12 <0.001 74 ± 6 61 ± 12 <0.001
Framingham 15 ± 11 11 ± 11 0.003 14 ± 11 13 ± 11 0.231 17 ± 12 13 ± 11 0.127
SCORE 3.1 ± 2.6 2.0 ± 2.2 0.001 3.2 ± 2.0 2.5 ± 2.7 <0.001 4.1 ± 2.0 2.6 ± 2.6 0.002
GFR (mL/min/1.73 m2) 86 ± 24 88 ± 20 0.560 83 ± 21 89 ± 23 0.131 78 ± 18 83 ± 23 0.176
CAC 302 ± 745 96 ± 233 <0.001 490 ± 994 102 ± 229 <0.001 1014 ± 1571 156 ± 383 0.001
Calcified plaque 72.3 % 40.7 % <0.001 82 % 51.5 % <0.001 92.3 % 58.6 % 0.017
Coronary Ather. 72.7 % 40.7 % <0.001 72.7 % 40.7 % <0.001 69.2 % 47.9 % 0.140
Obstructive CAD 29 % 9.3 % 0.005 44 % 11.5 % <0.001 53.8 % 19.1 % 0.004
Number of vessels with obstructive CAD 0: 94.4 % 0: 78 % 0.031 0: 68 % 0: 91.3 % 0.001 0: 61.5 % 0: 85.8 % 0.007
1: 3.7 % 1: 155 1: 22 % 1: 5.8 % 1: 15.4 % 1: 10.6 %
>1: 1.9 % >1: 7 % >1: 10 % >1: 2.9 % >1: 23.1 % >1: 3.5 %
AoVC aortic valve calcification; Ather atheroslcerosis; CAC coronary artery calcium; CAD coronary artery disease; DBP diastolic blood pressure; Family history Family
history of coronary artery disease; GFR glomerular filtration rate; p significance level; PP pulse pressure; SBP systolic blood pressure
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age: effect size 0.392, p > 0.001. Considering all these
variables on multivariate analysis, age and CAC were in-
dependent predictors of obstructive CAD (Table 5).
AoVC on top of CAC for the decision of whether or not to
proceed with CTA
The predictive model of obstructive CAD based on CAC
and AoVC had a good calibration (Hosmer and Leme-
show test: p = 0.155). On ROC curve analysis, the pre-
dictor model showed a good discriminatory power for
obstructive CAD, numerically higher than isolated CAC or
AoVC (Fig. 1), but without reaching statistical significance,
with a difference between AUC of 0.004, 95 % CI: −0.0170
to 0.0258, p = 0.684.
The secondary endpoint was reached in 5.9 % (2 of 34)
of patients with AoVC >454, and in 29.4 % (10 of 34) of
patients with AoVC >61.
The NRI of CAC >400 or AoVC >454 (vs isolated
CAC > 400) to not perform CTA was 2.5 %: 5.9 % (2 out
of 34) more patients with obstructive CAD would not
undergo CTA while 3.3 % (4 out of 120) more patients
without obstructive CAD would be spared CTA. Run-
ning the same test using the threshold AoVC >61 led to
an NRI of 7.7 %, where 29.4 % (10 out of 34) more
patients with obstructive CAD and 21.6 % (26 out of
120) more patients without obstructive CAD would not
perform CTA.
Discussion
These data have shown that AoVC is associated with ob-
structive CAD and CAC. We observed that AoVC can
be used to improve the reclassification of high CAD
probability in patients with AoVC >61. Indeed, AoVC
may be used to refine CAC, providing support to the de-
cision of not to proceed with CTA, thus preventing un-
necessary exposure to radiation and iodinated contrast
resulting from CTA, that would be futile and inappropri-
ate in patients with obstructive CAD.
This report is innovative because it assesses the useful-
ness of AoVC as a gatekeeper for CTA, on top of CAC.
On ROC curve analysis, the predictor model created by
association of AoVC to CAC showed higher discrimin-
atory power than CAC alone, although this difference
was not statistically significant. As ROC curve analysis
may lack sensitivity, other methods have been proposed
for assessing and comparing the accuracy of different risk
classifications. Net reclassification improvement index
evaluates whether a new model provides a more accurate
stratification into higher or lower risk categories of clinical





AoVC ≥1 AoVC >61 AoVC >454
OR 95 % CI p OR 95 % CI p OR 95 % CI p
Age 1.100 1.057-1.146 <0.001 1.183 1.09-1.261 <0.001 1.209 1.079-1.355 0.001
CAD ———— ———— ———— 4.859 1.694-13.938 0.003 ———— ———— ————
Pulse pressure 1.027 1.007-1.048 0.008 ———— ———— ———— 1.039 1.003 1.077
AoVC aortic valve calcification; CAD coronary artery disease; p – significance level
Table 4 Predictors of obstructive coronary artery disease on univariate analysis
Predictors of obstructive CAD: univariate analysis Without Obstructive CAD With Obstructive CAD p
Male gender, n% (n) 38.3 % (46) 58.8 % (20) 0.033
Dyslipidemia, % (n) 60.7 % (71) 79.4 % (27) 0.044
Hypertension 84.7 %(100) 85.3 % (29) 0.937
Diabetes 24.8 % (29) 20.6 % (7) 0.613
Family history of CAD 3.6 %(4) 6.1 % (2) 0.528
Cigarette smoking 17.6 % (6) 14.5 % (17) 0.656
Age >64 45.5 % (55) 73.5 % (25) 0.004
SCORE ≥3 28.2 % (33) 61.8 % (21) <0.001
Framingham ≥11 45.3 % (53) 61.8 % (21) 0.091
CAC ≥400 3.3 % (4) 50 % (17) <0.001
AoVC ≥1 59.2 % (71) 85.3 % (29) 0.005
AoVC >61 23.3 % (28) 64.7 % (22) <0.001
AoVC >454 5 % (6) 20.6 % (7) 0.004
AoVC aortic valve calcification; CAC coronary artery calcium; CAD coronary artery disease; p – significance level
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importance [17]. The treshold of AoVC 61 allowed a bet-
ter reclassification of 7.7 % of patients, which as practical
relevance once determination of AoVC is easy, fast and
can be performed in the same acquisition of CAC, without
increasing risks or costs for each patient. Indeed, it would
avoid unnecessary exposure to radiation and iodinated
contrast, and would reduce costs related to CTA in 29.4 %
of patients with CAD.
The exposure to ionizing radiation is a matter of con-
cern. The effective dose of radiation used in this study
was similar to that reported by other groups [18–21].
CAC (and AoVC) was performed with a relatively low
radiation exposure (0,8 mSv), whereas CTA increased
the exposure to radiation in about 10,44 mSv, what
could have been avoided in 29.4 % of patients with CAD,
by using the AoVC. Moreover, these patients will possibly
perform invasive angiography, being exposed to further
3-5 mSv [20, 22].
The volume of iodinated contrast medium used was
also similar to that reported by other groups [21–24].
It is related to costs [25] and possible complications,
and could be avoided in some patients by using
AoVC.
Still, CTA is significantly more expensive than CAC
(costs per study in Portugal: isolated CAC 80€; complete
study with CTA 207,1€) [25], and the use of AoVC could
reduce unnecessary costs in 29.4 % of patients with
CAD. The use of CTA in the acute setting also showed
to reduced the costs of care for patients presenting with
chest pain and low- or intermediate-risk [26]; for these
patients, refining the decision of proceeding with the
CTA would be even more important.
In the study population, AoVC was associated to calci-
fied plaques, atherosclerosis, higher levels of CAC,
prevalence and extension of obstructive CAD. Sub-
studies of ROMICAT (The Rule Out Myocardial Infarc-
tion using Computer Assisted Tomography) trial [11]
and MESA (The Multi-Ethnic Study of Atherosclerosis)
[12] have already demonstrated the relationship of
AoVC with the presence and extent of CAC. AoVC was
also a marker of the extent and severity of coronary ar-
tery disease evaluated by invasive angiography in a sam-
ple of 99 patients [13]. Nevertheless, to the best of our
knowledge, this is the first report of AoVC as a predictor
of obstructive CAD detected by CTA.




OR 95 % CI p
Age 1.066 1.013-1.122 0.014
CAC 1.005 1.003-1.007 <0.001
CAC coronary artery calcium; CAD coronary artery disease; CI confidence
interval; p – level of significance
Fig. 1 ROC curves for the discrimination of obstructive coronary artery disease: AoVC – AUC 0.749, 95%CI 0.837-0.955, p < 0.001; CAC – AUC 0.896,
95%CI 0.837-0.955, p < 0.001; PM CAC + AoVC – AUC 0.900, 95%CI 0.838-0.962, p < 0.001; SCORE – AUC 0.690, 95%CI 0.577-0.802, p < 0.001;
Framingham 0.596, 95%CI 0.471-0.721, p = 0.120. Legend: AoVC - aortic valve calcification; CAC - coronary artery calcium; CAD - coronary artery
disease; PM CAC + AoVC: predictor model of obstructive CAD based on coronary artery calcium and aortic valve calcification
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AoVC was associated with obstructive CAD in all the
evaluated cutoffs and had a good discriminatory power
for identifying obstructive CAD, as illustrated by ROC
curve analysis.
The AoVC cutoff value = 61 was the threshold with
the best amount of sensitivity and specificity for ob-
structive CAD. The latter was associated with higher
levels of AoVC and was an independent predictor of
AoVC >61, but this was not verified for the other cut-
offs. These data suggest the AoVC cutoff value = 61 as a
better indicator of CAD than the value 454, which was
equivalent to the threshold of CAC = 400 specificity-
wise. The cutoff 61 also achieved a higher net reclassifi-
cation index, proving to be the most suitable to use as
gatekeeper for CTA, on top of CAC.
An association of traditional cardiovascular risk fac-
tors, such as hypertension, diabetes, hyperlipidemia, age
and male gender, to the presence of AoVC has been pre-
viously described [8, 9]. In our sample, age and pulse
pressure were associated with AoVC, but no association
was found regarding other classical risk factors. They
were predictors of higher levels of AoVC, but they were
not independent of each other. AoVC was also associ-
ated to higher cardiovascular risk defined by SCORE,
similarly to what has been observed with other cardio-
vascular risk classification schemes [9].
Obstructive CAD was also associated with age, and
with risk factors as male gender and dyslipidemia.
Limitations
Our study has several limitations. We describe results of
a single-centre study, with a limited number of enrolled
patients. A larger sample would better assess the reclas-
sification capabilities of AoVC. Our data were retro-
spectively collected and evaluated, precluding a better
definition of the cardiovascular risk factors evaluated.
The definition of these risk factors was based on self-
reporting while doing history-taking or in the use of spe-
cific therapy, which may have underestimated its true
prevalence in this population and could act as a con-
founding factor for the evaluation of AoVC predictors.
Conclusions
AoVC is associated with the prevalence and the extent
of CAC, and with obstructive CAD on CTA. This associ-
ation remains even when AoVC is corrected for age.
AoVC is an easy and fast method and its use for the im-
provement of the selection of patients for CTA, on top
of CAC values, may justify further evaluation.
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